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Abstract: Background: Essential oils (EOs) are recommended by some veterinarians to treat otitis
externa in pets, but data about their efficacy in scientific literature are very scant. Methods: Nine
commercial EOs, from roman chamomile (Anthemis nobilis L.), star anise (Illicium verum), lavender
(Lavandula hybrida), litsea (Litsea cubeba (Lour.) Pers.), basil (Ocimum basilicum L.), oregano (Origanum
vulgare L. subsp. hirticum), rosemary (Rosmarinus officinalis L.), clary sage (Salvia sclarea L.), and
thyme (Thymus vulgaris L.) were tested against bacterial and fungal pathogens previously isolated
from dogs and cats with otitis externa. In particular, the analyses were carried out against
Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus pseudointermedius, Aspergillus niger,
Aspergillus fumigatus, Aspergillus terreus, Candida albicans, Candida tropicalis, Trichosporon sp., and
Rhodotorula sp. Results: O. vulgare and S. sclarea showed superior antibacterial activity, even if
not against all the strains. Trichosporon sp., C. albicans, and A. terreus were insensitive to most Eos,
while other yeasts and molds showed different degrees of sensitivity. In particular, most fungi were
inhibited by O. vulgare and R. officinalis. Conclusions: The obtained results suggest that some EOs
could be included in treatment as an alternative therapeutic option in bacterial otitis complicated by
fungi, in association with conventional drugs.
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1. Introduction
Otitis externa is an inflammation of the external ear canal. Several predisposing factors in dogs
and cats would be anatomic breed conformation, immunologic and endocrinopathic conditions, foreign
material, trauma, and treatments. Various microorganisms can colonize the external ear canal, and
they can proliferate with damage or inflammation due to primary factors [1]. Bacteria, yeasts, and
parasites are common causes of otitis externa.
Among bacteria, staphylococci—mainly Staphylococcus pseudointermedius (formerly Staphylococcus
intermedius [2]) and Staphylococcus aureusx—and Pseudomonas spp. are often isolated from ears of dogs
and cats with acute or chronic otitis externa.
About 27% of cases of otitis externa are reported as being caused by fungi, mainly by Malassezia
pachydermatis [3]. Other fungi more or less frequently involved are Aspergillus niger, Aspergillus
fumigatus, Aspergillus terreus [4], and several yeasts, such as Candida albicans [5,6], Candida parapsilosis,
Trichosporon cutaneum, and Cryptococcus laurentii [7], as well as Candida tropicalis [6,8] and Rhodotorula [9].
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Antibiotic and/or antifungal treatments do not always resolve otitis externa in pets; conversely,
they can worsen the situation, causing secondary and recurring infections.
The use of some essential oils (EOs) against otitis externa in pets is currently recommended by
some veterinarians that—based on their experience—obtained good results in the treatment of these
infections. However, data about the efficacy of EOs against bacteria and yeasts related to canine and/or
feline otitis are not available in the scientific literature, with the exception of reports on M. pachydermatis
otitis externa [10]; furthermore, information about human cases are very scant [11–13].
The aim of this study was to evaluate the in vitro antibacterial and antifungal activities of EOs
against the most frequent pathogens isolated from the ears of dogs and cats with otitis externa.
EOs have been selected for their effectiveness as reported in literature and for their availability on
the market.
2. Material and Methods
2.1. Essential Oils
The study was performed employing the following nine EOs: roman chamomile (Anthemis nobilis
L.), star anise (Illicium verum), lavender (Lavandula hybrida), litsea (Litsea cubeba (Lour.) Pers.), basil
(Ocimum basilicum L.), oregano (Origanum vulgare L. subsp. hirticum), rosemary (Rosmarinus officinalis
L.), clary sage (Salvia sclarea L.), and thyme (Thymus vulgaris L.).
All EOs were acquired from the producer (FLORA®, Pisa, Italy). They were maintained at 4 ◦C in
dark glass vials and were microbiologically analyzed for quality control before use.
2.2. Gas Chromatography–Mass Spectrometry Analysis
The GC analysis was performed as previously described [14].
2.3. Antibacterial Activity
2.3.1. Bacterial Strains
Each EO was tested against three bacterial strains: Pseudomonas aeruginosa, S. aureus, and
S. pseudointermedius. All the isolates were previously obtained from cases of otitis externa of dogs
and/or cats, typed, and stored at −80 ◦C in glycerol broth.
2.3.2. Agar Disc Diffusion Method
Antibacterial activity of each EO was tested by Kirby-Bauer agar disc diffusion method following
the previously described procedures [15,16].
Bacterial strains were also tested by Kirby-Bauer method to evaluate their in vitro sensitivity to the
following antibiotics (Oxoid): amikacin (30 µg), amoxycillin–clavulanic acid (30 µg), ampicillin (10 µg),
cefotaxime (30 µg), ceftazidime (30 µg), cephalexin (30 µg), ciprofloxacin (5 µg), erythromycin (10 µg),
enrofloxacin (5 µg), streptomycin (10 µg), sulphametoxazole–trimethoprim (25 µg), and tetracycline
(30 µg). The results were interpreted as indicated by the National Committee for Clinical Laboratory
Standards (NCCLS) [17].
2.3.3. Minimum Inhibitory Concentration
Each bacterial strain resulting sensitive to the EOs in the Kirby-Bauer test was submitted to the
determination of the minimum inhibitory concentration (MIC).
MIC was tested with agar disc diffusion method, adding 10 µL of 10%, 5%, 2.5%, 1.25%, 0.62%,
0.31% (v/v) of each EO. Results were successively calculated as µg/µL. All tests were performed
in triplicate.
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2.4. Antimycotic Activity
2.4.1. Fungal Strains
Clinical isolates of A. niger, A. fumigatus, A. terreus, C. albicans, C. tropicalis, Trichosporon sp., and
Rhodotorula sp. obtained from dogs and cats suffering from otitis externa were employed for testing.
Molds were stored at −20 ◦C on potato dextrose agar, and yeasts were maintained in distilled water at
room temperature.
2.4.2. Microdilution Test
MICs were determined by a microdilution test carried out as reported elsewhere [15], starting
from a dilution of 5% (v/v), following the methods described by Clinical and Laboratory Standards
Institute M38A2 [18] for molds and Clinical and Laboratory Standards Institute M27A3 [19] for yeasts.
3. Results
3.1. Gas Chromatography–Mass Spectrometry Analysis
The composition of the assayed EOs is presented in Table 1. All these oils were rich in
monoterpenes, except for A. nobilis, where non-terpenic esters such as isobutyl angelate (34.5%)
and isoamyl angelate (18.7%) were the most represented constituents. The main terpenes identified in
the EO of O. vulgare and T. vulgaris were carvacrol (65.9%) and thymol (52.6%), respectively, followed by
p-cymene (15.3%) only in T. vulgaris. Linalyl acetate was evidenced in S. sclarea as the main constituent
(54.7%). Linalool was the most important compound in the EO of O. basilicum and L. hybrida (46.0%
and 31.5%, respectively). It is also important to highlight the presence of eugenol in O. basilicum
with a significant percentage (11.5%) and linalyl acetate in L. hybrida (26.8%). The EO of I. verum was
characterized by the presence of a good amount of anethol (89.8%). More represented constituents of
L. cubeba were neral and geranial (32.5% and 36.4%, respectively), while R. officinalis was characterized
by 37.9% of α-pinene, followed by 1,8-cineole (22.0%).
Table 1. Relative percentage of the main constituents of tested essential oils (EOs).
N. Class Component RI A.n O.v O.b S.s T.v I.v R.o L.c L.h
1 est propyl butanoate 898 5.5
2 mh tricyclene 926 1.4 1.5
3 mh α-pinene 940 1.2 37.9
4 mh camphene 953 5.4
5 mh sabinene 976 1.0
6 est isopropyl tiglate 976 1.7
7 mh β-pinene 980 5.0 1.2
8 nt 6-methyl-5-hepten-2-one 985 1.5
9 mh myrcene 991 2.2 1.6
10 est isobutyl isovalerate 1005 1.3
11 est 2-methylbutyl isobutyrate 1015 4.5
12 mh α-terpinene 1018 2.1
13 mh o-cymene 1026 1.1
14 mh p-cymene 1026 9.3 15.3
15 mh limonene 1031 3.9 3.3 16.3
16 om 1,8-cineole 1033 5.9 22.0 2.3 7.7
17 mh (Z) β-ocimene 1040 1.2
18 mh (E) β-ocimene 1050 2.1
19 est isobutyl angelate 1053 34.5
20 mh γ-terpinene 1062 5.3 2.9 0.5
21 mh artemisia ketone 1065 7.4
22 om cis-linalool oxide (furanoid) 1074 2.2
23 om trans-linalool oxide (furanoid) 1088 1.8
24 est isobutyl tiglate 1093 1.5
25 om trans-sabinene hydrate 1097 1.8 3.8
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Table 1. Cont.
N. Class Component RI A.n O.v O.b S.s T.v I.v R.o L.c L.h
26 om linalool 1098 46.0 8.1 1.5 31.5
27 om trans-pinocarveol 1142 1.7
28 om camphor 1143 7.6 7.3
29 est propyl tiglate 1153 5.3
30 est isoamyl angelate 1162 18.7
31 om borneol 1165 1.6 2.0 2.1
32 om pinocarvone 1166 2.7
33 om terpinen-4-ol 1177 2.4 4.0
34 om α-terpineol 1189 2.1
35 unknown 1.7
36 pp methyl chavicol (=estragol) 1195 1.1
37 om thymol methyl ether 1232 1.7
38 om neral 1240 32.5
39 om linalyl acetate 1257 54.7 26.8
40 om geranial 1270 36.4
41 pp (E)-anethol 1283 89.8
42 om isobornyl acetate 1285 1.6 3.3
43 om bornyl acetate 1285 2.4
44 om thymol 1290 52.6
45 om carvacrol 1298 65.9
46 om (E)-8-hydroxylinalool 1345 5.6
47 om (Z)-8-hydroxylinalool 1360 15.8
48 pp eugenol 1356 11.5
49 sh β-elemene 1392 2.2
50 sh β-caryophyllene 1418 3.7 6.8 4.1 2.2
51 sh trans-α-bergamotene 1437 3.6
52 sh α-guaiene 1440 1.1
53 sh (E)-β-farnesene 1458 1.4
54 sh germacrene D 1481 3.5
55 sh α-bulnesene 1505 2.0
56 sh trans-γ-cadinene 1513 2.8
57 sh δ-cadinene 1524 1.0
58 os caryophyllene oxide 1581 4.8 0.3
59 os 1,10-di-epi-cubenol 1614 1.0
60 os t-cadinol 1640 5.8
61 od sclareol 2223 1.3
Total% 92.1 98.5 99.2 98.9 95.6 100.0 97.4 99.4 100.0
Legend: RI: Retention index measured on HP-5 column; Compounds present in percentage <1% were excluded
from the table. A.n.: Anthemis nobilis; I.v.: Illicium verum; L.h.: Lavandula hybrid; L.c.: Litsea cubeba; O.b.: Ocimum
basilicum; O.v.: Origanum vulgare subsp. hirticum; R.o.: Rosmarinus officinalis; S.s.: Salvia sclarea; T.v.: Thymus vulgaris;
mh: monoterpene hydrocarbons; om: oxygenated monoterpenes; sh: sesquiterpene hydrocarbons; os: oxygenated
sesquiterpenes; nt: non-terpenes; pp: phenylpropanoids; od: oxygenated diterpenes; est: non-terpenic esters.
3.2. Antibacterial Activity
The results obtained in this investigation showed that the assayed EOs had different degrees of
growth inhibition against the three tested bacterial isolates (Table 2).
Table 2. The inhibition zones obtained testing the selected bacterial strains against the assayed EOs.
Bacterial Strains
Staphylococcus aureus Staphylococcus pseudointermedius Pseudomonas aeruginosa
Essential Oils
M SD M SD M SD
Anthemis nobilis 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Illicium verum 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Lavandula hybrida 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Litsea cubeba 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Ocimum basilicum 0.0 ± 0.0 7.0 ± 0.0 1 8.0 ± 0.0 2
Origanum vulgare 13.3 ± 0.6 3 17.3 ± 0.6 4 0.0 ± 0.0
Rosmarinus officinalis 0.0 ± 0.0 0.0 ± 0.0 7.0 ± 0.0 5
Salvia sclarea 0.0 ± 0.0 14.3 ± 0.6 6 8.0 ± 0.0 7
Thymus vulgaris 8.3 ± 0.6 8 0.0 ± 0.0 0.0 ± 0.0
Legend: M: mean expressed in mm; MIC: minimum inhibitory concentration; SD: standard deviation. 1 MIC: 18.34
µg/µL; 2 MIC: 18.34 µg/µL; 3 MIC: 2.36 µg/µL; 4 MIC: 1.18 µg/µL; 5 MIC: 18.28 µg/µL; 6 MIC: 2.23 µg/µL; 7 MIC:
17.86 µg/µL; 8 MIC: 18.73 µg/µL.
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A. nobilis, I. verum, L. hybrida, and L. cubeba had no activity against the three tested bacteria.
S. sclarea showed good activity against S. pseudointermedius, with an MIC value of 2.23 µg/µL and
scarce activity against P. aeruginosa (MIC of 17.86 µg/µL). O. vulgare inhibited the growth of S. aureus
and S. pseudointermedius, with MIC values of 2.36 µg/µL and 1.18 µg/µL, respectively; on the other
hand, no activity was observed against P. aeruginosa. Very low antimicrobial activity was observed for
the remaining EOs. DMSO, tested as negative control, did not cause growth inhibition.
P. aeruginosa was resistant to eleven antibiotics and susceptible only to amikacin; S. aureus
were susceptible to tetracycline, amoxicillin–clavulanic acid, erythromycin, and sulphametoxazole–
trimethoprim; S. pseudointermedius was susceptible only to amoxicillin–clavulanic acid (Table 3).
Table 3. The inhibition zones (expressed in mm) obtained testing the selected bacterial strains against
different antibiotics (standard deviation was equal to 0).
Bacterial Strains
Staphylococcus aureus Staphylococcuspseudointermedius
Pseudomonas
aeruginosa
Antibiotics
Amikacin 7 (R) 9 (R) 17 (S)
Amoxycillin–clavulanic acid 27 (S) 26 (S) 0 (R)
Ampicillin 16 (R) 15 (R) 0 (R)
Ceftazidime 0 (R) 0 (R) 0 (R)
Cephalexin 0 (R) 0 (R) 0 (R)
Cephotaxime 0 (R) 0 (R) 13 (R)
Ciprofloxacin 10 (R) 0 (R) 0 (R)
Enrofloxacin 14 (R) 0 (R) 0 (R)
Erythromycin 17 (S) 0 (R) 0 (R)
Streptomycin 0 (R) 0 (R) 0 (R)
Sulphametoxazole–trimethoprim 24 (S) 0 (R) 0 (R)
Tetracycline 20 (S) 0 (R) 0 (R)
Legend: S: susceptible; R: resistant.
3.3. Antimycotic Activity
Tested fungal isolates showed different sensitivity patterns to assayed EOs. The overall lowest
MIC values were reported for O. vulgare and R. officinalis. S. sclarea, R. officinalis, and T. vulgaris had
MIC values <0.3 µg/µL against C. tropicalis, while O. vulgare showed a good antifungal activity against
aspergilli. Trichosporon sp. appeared to be sensitive to R. officinalis only, while Rhodotorula sp. was
inhibited from R. officinalis and O. vulgare. This latter EO was the sole active when tested against
C. albicans. Detailed results are reported in Table 4.
Table 4. MIC values (expressed in µg/µL) of tested EOs versus selected fungal agents (standard
deviation was equal to 0).
Fungal Agents
Essential Oils Candidaalbicans
Candida
tropicalis
Aspergillus
niger
Aspergillus
terreus
Aspergillus
fumigatus
Trichosporon
sp.
Rhodotorula
sp.
Anthemis nobilis 4.50 4.50 4.50 4.50 2.25 4.50 4.50
Illicium verum 2.44 4.88 2.44 2.44 0.59 9.78 2.44
Lavandula hybrida 4.25 4.25 2.12 >8.50 8.50 >8.50 4.25
Litsea cubeba 4.43 2.21 0.53 2.21 0.18 8.86 4.43
Ocimum basilicum 2.29 4.58 1.10 4.58 2.29 9.17 1.10
Origanum vulgare 0.19 1.14 0.19 0.19 0.19 2.37 0.19
Rosmarinus officinalis 9.14 0.29 0.29 >9.14 0.29 0.46 0.29
Salvia sclarea 1.07 0.18 2.23 4.46 2.23 >8.93 >8.93
Thymus vulgaris 5.72 0.19 0.56 11.71 5.72 11.71 5.72
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4. Discussion
The bacterial strains analyzed in this study have previously been isolated from pets with chronic
otitis externa. These strains resulted multiresistant to several antibiotics, and for this reason they
caused problems in therapy.
S. aureus has been isolated from several body sites of dogs and cats—in particular from skin,
anterior nares, and anal region. Staphylococci seem to be transferred from the nose and mouth of the
dog to its coat and ears by grooming and pruritic behaviors [20].
S. pseudointermedius is part of the microflora of the upper respiratory tract, mucosal, and skin
surfaces of dogs and cats; moreover, it may be an invasive pathogen determining some pathologies,
including otitis. Resistance of S. aureus and S. pseudintermedius to classical antibiotics used in clinical
veterinary therapy is an increasing threat [21].
P. aeruginosa is an opportunistic, ubiquitous bacterial pathogen that can be isolated from the tissue
of healthy animals, and has been determined to be the distinct cause of several infections, including
chronic otitis externa. An increasing number of P. aeruginosa strains resistant to several antibiotics has
been observed in recent years [22].
The results of this study show that not all EOs have activity against the tested bacterial strains.
EO of O. vulgare gave good results only against staphylococci, in accordance with other studies
that consider this EO as an effective antistaphylococcal natural product.
The major compounds of oregano EO—carvacrol, thymol, and terpenoids—seem to determine
the antimicrobial activity [23], and it is speculated that they disrupt the membrane of bacteria; in
particular, they sensitize the phospholipid bilayer of the cell membrane, increasing the permeability
and leakage of vital intracellular constituents [24].
Previous studies found that S. sclarea is active against staphylococci, including S. aureus [25],
whereas we found that the tested S. aureus strain was resistant. However, data about the antimicrobial
activity of S. sclarea are mainly related to food pathogens, whereas no information is available about its
clinical use.
Trichosporon sp., C. albicans, and A. terreus were insensitive to most EOs evaluated in the present
study, while other fungi showed different degrees of sensitivity. C. tropicalis was reported as sensitive
when tested against S. sclarea, R. officinalis, and T. vulgaris, confirming previously reported data
concerning this latter EO [15,26].
O. vulgare has a known antimicrobial effect [26,27] due to the high amount of carvacrol, confirming
the results of our study.
R. officinalis yielded interesting results showing its efficacy, which appear to be in agreement with
Fu et al. [28] for A. niger, but not for C. albicans. Our results confirm the effectiveness of O. vulgare
against A. niger and Rhodotorula sp., and the ineffectiveness of I. verum against A. niger, reported by
Elgayyar et al. [27], but would not corroborate data referred to both O. basilicum and R. officinalis, as
well as the efficacy of I. verum against Rhodotorula sp.
Molds and yeasts tested in the present report were cultured from affected animals’ ears. Even if
antifungal drug resistance is not a common feature involving these agents, such alternative treatment
based on natural products could achieve the owners’ approval [10], but the choice of an EOs-based
treatment should take into account the identification of fungal organisms responsible for the disease
in order to select the most suitable product for treatment. In fact, the results obtained in the present
study would suggest that the analyzed EOs are not always able to replace antibiotics or antimycotic
drugs to treat such infections, being that their effectiveness is strictly related to the pathogen involved.
For example, in the case of P. aeruginosa isolate, the treatment with amikacin resulted better than the
use of EOs that, although active, had high MIC values (from 17.86 µg/µL to 18.34 µg/µL).
In the light of the above considerations, the first choice option would take into account the
causative agents of otitis with isolation and typing of the etiologic agent; successively, it would be
important to carry out an antimicrobial susceptibility test to select an appropriate therapy. EOs can
represent a good therapeutic tool, but considered that their efficacy is strongly related to the bacterial
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strain, it could be useful to evaluate the in vitro activity of different EOs in order to select a natural
product effective against the pathogen and that could improve the efficacy treatment.
In conclusion, EOs could be scheduled as an alternative therapeutic option in bacterial otitis
complicated by fungi in association with conventional drugs.
Author Contributions: V.V.E. and F.M. conceived and designed the experiments and wrote the paper; S.N., F.B.
and B.N. performed the experiments; V.V.E., F.M. and L.P. analyzed the data.
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